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Abstract
 .The dopaminergic neurotoxin N-methyl,4-phenyl-1,2,3,6 tetrahydropyridine MPTP causes a syndrome in primates and
 .humans which mimics Parkinson’s disease PD in clinical, pathological, and biochemical findings, including diminished
activity of complex I in the mitochondrial electron transport chain. Reduced complex I activity is found in sporadic PD and
can be transferred through mitochondrial DNA, suggesting a mitochondrial genetic etiology. We now show that MPTP
 q.treatment of mice and N-methylpyridinium MPP exposure of human SH-SY5Y neuroblastoma cells increases oxygen
free radical production and antioxidant enzyme activities. Cybrid cells created by transfer of PD mitochondria exhibit
similar characteristics; however, PD cybrids’ antioxidant enzyme activities are not further increased by MPPq exposure, as
are the activities in control cybrids. PD mitochondrial cybrids are subject to metabolic and oxidative stresses similar to
MPTP parkinsonism and provide a model to determine mechanisms of oxidative damage and cell death in PD. q 1997
Elsevier Science B.V.
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1. Introduction
 .Parkinson’s disease PD arises from the loss of
 .dopaminergic neurons in the substantia nigra SN ,
and can be produced experimentally following expo-
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sure to the neurotoxin N-methyl,4-phenyl-1,2,3,6-te-
 . w xtrahydropyridine MPTP 1,2 . N-methylpyridinium
 q.ion MPP , the active toxin and two electron oxida-
tion product of MPTP, is preferentially taken up by
dopamine neurons and concentrated into mitochon-
w xdria down the electrochemical gradient 3 , where it
selectively and potently inhibits complex I of the
 . w xelectron transport chain ETC 4 . This inhibition of
0925-4439r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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w xcomplex I leads to impaired ATP production 5 , loss
w xof the mitochondrial membrane potential 6 , and the
 . w xformation of reactive oxygen species ROS 3–7 .
Nigrostriatal MPTP neurotoxicity is also dependent
 . w xon nitric-oxide synthase NOS 8–10 , which forms
 fl.nitric oxide NO , a potential precursor to the toxic
 y.peroxynitrite anion ONOO and hydroxyl free radi-
 fl . w xcal OH 11,12 . These bioenergetic and oxidative
stresses likely contribute to the death of vulnerable
w xneurons 9,10,13,14 . Similar processes may occur in
PD, as mitochondria from multiple PD tissues includ-
w x w x w xing platelets 15 , fibroblasts 16 , muscle 17,18 ,
w x w xsubstantia nigra 19 and nonnigral brain 20,21 ex-
hibit significantly reduced complex I activity, sug-
gesting a systemic mitochondrial defect.
Parkinson’s SN contains markers of oxidative
w xdamage to lipids 22 , decreased total glutathione
w x w xcontent 23 , and increased levels of iron 24 , which
can catalyze the conversion of hydrogen peroxide
 . flH O into the highly reactive OH. These findings2 2
support the theory that ROS may contribute to neu-
ronal injury and eventual cell death in PD
w x9,10,13,14,20 .
Mechanisms of protection from oxidative free radi-
cal damage include scavenging enzyme systems which
fly detoxify ROS such as superoxide, O superoxide2
. dismutase, SOD or H O catalase, CAT and glu-2 2
.tathione peroxidase, GPX . Intracellular glutathione
functions as both a general free radical scavenger and
a substrate for GPX when in its reduced form, which
is continuously regenerated by glutathione reductase
 .GRD . We measured ROS production and the activi-
ties of these major antioxidant enzymes, and found
that they are all increased in brains of mice treated
with MPTP, in SH-SY5Y cells exposed to MPPq,
and in PD cybrid cells carrying the genetically trans-
mitted complex I defect found in PD mitochondria.
2. Materials and methods
2.1. MPTP treatment of mice
We monitored the time course and brain regional
distribution of production of flOH and changes in
antioxidant enzyme activities in C57BLr6 black mice
treated systemically with MPTP. We treated male
 .C57BLr6 mice with MPTP intraperitoneally i.p.
24 mgrkg b.i.d. for up to 48 h maximum MPTP
.dose was 96 mgrkg .
2.2. Antioxidant enzymes in MPTP-treated mice
6 mice were sacrificed at each time-point 0, 2, 8,
.24, 32, 48, 72, and 96 h by decapitation and immedi-
ately put on ice and the brains dissected and placed
on dry ice. The frontal cortex, striatum, ventral mid-
 .brain which includes the SN , and cerebellum were
 .isolated and placed in ice-cold PBS 20X volumes .
The tissues were kept at y808C until ready. Within 2
weeks, the tissues were thawed, 0.013% sodium
cholate was added to lyse subcellular organelles, they
were sonicated with an ultrasonic tip Ultrasonics,
.Inc, Farmington, N.Y. for one minute, and cen-
trifuged at 12,000X g for 10 min at 48C to pellet out
insoluble materials. The supernatants were then kept
on ice until the biochemical assays were performed.
Neither the freezerthawing of tissues nor the addi-
tion of this concentration of sodium cholate had
discernible adverse effects on antioxidant enzyme
activities.
2.3. Hydroxyl radical measurements in MPTP-treated
mice
For the hydroxyl radical measurements, 4 or 5
mice were sacrificed at each time-point 0, 8, 24, 48,
.72, and 168 h , after having received 100 mgrkg
salicylic acid i.p one hour prior to decapitation. The
isolated regions were frozen on dry ice, weighed,
sonicated in 20 volumes of ice-cold 0.1 M HCLr0.1%
sodium metabisulfite and centrifuged. Brain regional
flOH was estimated in supernatants by HPLC assay
 .of tissue 2,3-dihydroxbenzoic acid 2,3-DHB , the
stable and specific adduct between flOH and salicy-
w xlate 25 .
2.4. Antioxidant enzyme acti˝ity measurements
Measurements of enzyme activities were per-
formed according to standard methods. The SOD
w xassay was done according to Nagi 26 , via inhibition
of the reduction of NBT by superoxide radical pro-
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.duced from oxidation of glucose by glucose oxidase ,
using 2 mM KCN to inhibit the CuZn form and
measure the activity of the Mn form, and using
 .Sigma SOD as a reference 1Us45 ng to generate a
standard curve. The CuZn SOD activity was deter-
mined by subtracting the Mn SOD from total SOD
activity. GRD activity was measured according to
w xCarlberg and Mannervik 27 by monitoring the oxi-
dation of NADPH at 340 nm in the presence of
GSSG. Selenium-dependent GPX activity was mea-
w xsured according to Carmagnol et al. 28 via coupling
to the oxidation of NADPH by excess GRD moni-
tored at 340 nm. The CAT assay was performed
according to the spectrophotometric method of Aebi
w x29 , monitoring the degradation of H O at 240 nm.2 2
2.5. Treatment of SY5Y neuroblastoma cells for
enzyme assays
We measured antioxidant enzyme activities in con-
trol and SH-SY5Y cells exposed to 50 mM MPPq.
This concentration was chosen as one which should
inhibit complex I, and was found to have an effect on
the antioxidant enzymes, and yet produces negligible
cell death in serum-containing media. We also mea-
sured antioxidant enzyme activities in SY5Y cells
exposed to 96 h of 100 mM Se with or without 48 h
MPPq treatment, to determine whether this would
further upregulate GPX activities. The SY5Y cells
were grown in media of Dulbecco’s modified Eagle
 .medium DMEM, Gibco BRL, Gaithersburg, MD
supplemented with 10% nondialyzed fetal bovine
 .serum Intergen, Purchase, NY and 1X
penicillinrstreptomycin. The cells were grown to
confluence, and 60–70 million cells were harvested
for each sample with 5% trypsin–EDTA, washed
twice with and suspended in 1 ml PBSr40 million
cells. Cells were frozen at y808C until assays, then
 .were homogenized in sodium cholate 0.013% and
sonicated for 6 min at 50% duty cycle, then cen-
trifuged for 10 min at 12,000X g at 48C to isolate the
supernatants. The cells were kept frozen no longer
than 2 weeks, and neither the freezing and thawing
nor this concentration of sodium cholate had any
discernable adverse effects on enzyme activities. The
supernatants were then assayed, with all samples
being kept on ice, and the procedure repeated at least
thrice for each time point.
2.6. Measurements of ROS in SY5Y cells
Intracellular reactive oxygen species were esti-
 .mated with 2,7-dichlorofluorescin diacetate DCFA
fluorescence combined with flow cytometry. DCFA
is a cell-permeant nonfluorescent compound which is
cleaved and retained intracellularly, and is converted
by peroxides into fluorescent dichlorofluorescein
 . w xDCF 30 . SY5Y cells were incubated for 45 min
 .with 10 mM DCFA Molecular Probes, Eugene OR
in serum-free DMEM medium containing a final
w xDMSO of 0.05%. Cells were harvested with 5%
trypsin, resuspended in DMEM and assayed on a
Beckman-Dickinson FACS Station, using 488 nm ex-
citation and 530r30 bp filter for detection. For each
assay of MPPq effects, an equal number of events
from cells not exposed to MPPq were also assayed.
Data are expressed as average ratios of mean fluores-
cence of MPPq treated cellsrmean fluorescence of
w qxcontrol cells. Each MPP was assayed in three
independent experiments.
2.7. Creation and treatment of PD cybrid cell lines
A clonal stock of human SH-SY5Y neuroblastoma
 0cells lacking mtDNA rho cells, MitoKor Corpora-
.tion, San Diego, CA was created by prolonged expo-
sure of these cells to low concentrations of ethidium
w xbromide, which selectively depletes mtDNA 31 .
Fusion of platelets from patients with sporadic PD
with these mtDNA-deficient clonal SH-SY5Y cells
w xwas performed as previously described 32 , resulting
in transfer of mitochondria and mtDNA. These cyto-
 .plasmic hybrid cells or ‘‘cybrids’’ were grown and
harvested in the same manner as the SY5Y cells,
except that their media was supplemented with
50 mgrml uridine. Each line was grown and har-
vested separately at least twice, and assayed blinded
at least once.
2.8. Statistical analyses
One way ANOVAs were performed on all enzyme
activity time courses to determine normality, and
post-hoc analyses were performed to determine sig-
nificance of individual time-points. Tukey’s test was
performed on parametric data sets and Dunnett’s test
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on nonparametric data sets for each time-point com-
pared to controls. T-tests were used to compare en-
zyme activities between Se-treated and control SY5Ys
and between cybrids and controls. SigmaStat soft-
 .ware Jandel Scientific was used for all statistical
tests.
3. Results
3.1. ROS production and antioxidant enzyme
acti˝ities in MPTP-treated mouse brains
We found evidence of increased ROS production
in the brains of MPTP-treated mice and concomitant
alterations in antioxidant enzyme activities in these
 .animals. As shown in Fig. 1 a , tissue levels of
2,3-DHB, the specific adduct between flOH and sali-
w xcylate 25 , increased significantly in the striatum and
ventral midbrain. We observed the greatest relative
increase in 2,3-DHB in the ventral midbrain, where
the cell bodies of the dopaminergic SN cells whose
q.striatal terminals concentrate MPP reside. We ob-
served much smaller changes in cerebellar levels of
2,3-DHB after MPTP treatment.
 .As shown in Fig. 1 b , we found regionally spe-
cific increases in antioxidant enzyme activities in
several brain regions. Overall, the greatest increases
in activities were found in striatum, where GPX rose
most significantly, by nearly 500%, and ventral mid-
brain, where total SOD, CAT, and GPX rose most
significantly, each to about 300% of baseline. Less
dramatic increases were found in the frontal cortex
and cerebellum. These results are consistent with the
selective nigrostriatal neurotoxicity of MPTP. Thif-
w xfault et al. 33 also recently showed that treatment of
mice with a different MPTP regime acutely upregu-
lated the activities of CAT in the SN and both
isoforms of SOD in the striatum; however, they
found decreased Mn SOD in the SN, failed to find
increases in GPX, and did not measure GRD activity.
3.2. ROS and antioxidant enzyme acti˝ities in
MPP q-treated SY5Y cells
We also detected significant increases in ROS and
scavenging enzyme activities in SY5Y neuroblastoma
cells treated with MPTP’s toxic metabolite, MPPq.
 .Fig. 1. Time course of changes in A hydroxyl radical produc-
 .tion and B antioxidant enzyme activities in the brains of
C57rBL6 mice treated with MPTP. Results for flOH measure-
ments are the means of data from 4–5 mice at each time point as
measured by 2,3-DHB trapping. Results for enzyme activities in
regions of the brains of MPTP-treated mice are means of data
from 6 mice at each time point and are expressed as percentage
of baseline control activity. CAT activity is measured in micro-
moles H O consumedrminrmg protein, SOD in units SODrmg2 2
protein, GRD and GPX as nanom oles NADPH
consumedrminrmg protein. The following CAT enzyme time
 .courses and time points were significant p-0.05 relative to
controls: frontal cortex, and at 2, 8, 32, 48, 72, and 96 h; striatum;
ventral midbrain and at 8, 24, 32, 48, 72, and 96 h; cerebellum at
72 h. The following total SOD enzyme time courses and time
 .points were significant p-0.05 relative to controls: frontal
cortex and at 48, 72, and 96 h; striatum; ventral midbrain and at
24, 32 h; cerebellum and at 72 h. The following GRD enzyme
 .time courses and time points were significant p-0.05 relative
to controls: striatum; ventral midbrain, and at 32 and 72 h;
cerebellum at 72 h. The following GPX enzyme time courses and
 .time points were significant p-0.05 relative to controls: frontal
cortex and at 2, 8, 32, and 48h; striatum and at 2, 8, 32, 48, 72,
and 96 h; ventral midbrain and at 2, 8, 24, 48, 72, and 96 h.
Intracellular ROS, monitored by appearance of DCF
fluorescence, increased after incubation with 50 mM
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MPPq and peaked after 6–12 h, then declined to near
  ..baseline by 48 h exposure Fig. 2 a . This rise and
fall in ROS detected in vitro with DCF fluorescence
may be analogous to our observed trend in brain flOH
 .production after MPTP treatment of mice. Fig. 2 b
shows that increasing concentration of MPPq in-
duced parallel increases in ROS levels in SH-SY5Y
cells. As it is known that MPPq inhibits complex I in
w xa dose-dependent manner 34 , these results suggest a
correlation between ROS production and degree of
ETC inhibition. At concentrations at or above about
q 500 mM MPP , cell death began to occur data not
.shown . As shown in Fig. 3, all the antioxidant
enzyme activities increased in the SH-SY5Ys, with
 .the Mn–SOD mitochondrial isoform and CAT ac-
tivities rising to the greatest degree approximately
.400% and 300%, respectively after exposure to
MPPq, similar to what we observed in vivo in mice
treated with MPTP.
Fig. 2. Time course of changes in DCFA fluorescence measured
with flow cytometry in SH-SY5Y cells exposed to 50 mM MPPq.
Data are means"sem from three independent experiments and
are expressed as fluorescence ratios for MPPq-treated cells com-
 .pared to simultaneously analyzed control untreated cells. The
 .  .6 h timepoint was significant ps0.034, unpaired t-test . B .
DCF fluorescence signal in SH-SY5Y cells exposed for 48 h to
w qxincreasing MPP . Data are results from three independent
experiments. The results were significant p-0.001, unpaired
. qt-test at 100, 500, and 1000 mM MPP .
Fig. 3. Increased antioxidant enzyme activities in SY5Y cells
treated with MPPq. All activities are expressed as in Fig. 1. Data
are from 3–4 independent experiments for each time point. The
following enzyme time courses and timepoints were significant
 .p-0.05 : CAT, and at 8, 24, 48, 72, and 96 h; CuZn SOD, and
24 h; Mn SOD, 24, 48, 72, and 96h; GRD, and 96 h; GPX, 8, 48,
and 96 h.
3.3. Antioxidant enzyme acti˝ities in selenium-treated
SY5Y cells
As recent reports in the literature have suggested
that standard serum-supplemented media do not con-
tain sufficient Se to allow maximal expression of
w xSe–GPX activities 35 , we determined the effects of
 .added Se on GPX and GRD activities Table 1 . We
treated cells for 96 h with 100 mM Se, a time period
and Se-concentration which were found to be effec-
tive in significantly upregulating GPX activity in the
SY5Y cells. This regimen produced significant eleva-
tions in both GPX and GRD, which presumably rose
in compensation for increased GSSG formed by ele-
vated GPX activity. The coincubation of Se with
50 mM MPPq further augmented the activities of
both GPX and GRD significantly compared to treat-
ment with MPPq alone. In contrast, the addition of
MPPq to Se-treated cells did not further increase
GPX activity, although it did significantly affect GRD
 .activity, compared to Se alone Table 1 .
3.4. Antioxidant enzyme acti˝ities in PD cybrids
The cybrid cells employed in this study all share
the same nuclear genes, and differ only in their
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Table 1
MPPq and Se-supplementation augment the activities of GPX
and GRD in SY5Y cells
Condition Mean activity Sem P P1 2
GPX activity
Control 40.2 3.57
qMPP 83.7 7.33 0.006 0.031
Se 106.7 2.60 -0.001 0.53
qSeqMPP 109.3 2.85 -0.001
GRD activity
Control 59.0 4.72
qMPP 78.0 4.89 0.049 0.025
Se 88.3 3.22 0.007 0.058
qSeqMPP 110.9 8.00 0.005
The SY5Y cells were treated and harvested and GPX and GRD
activities measured as in the methods. P is the p-value calculated1
from an unpaired t-test of the indicated condition compared to
 .control untreated . P is the p-value compared to the cells treated2
with MPPq and Se together. GRD and GPX activities are
measured in nanomoles NADPH consumedrminrmg protein.
mtDNA. Persisting alterations in cellular functions
after multiple cycles of cellular and mitochondrial
replication and division must, therefore, derive from
the source of mtDNA, not nuclear or environmental
factors. Our previous study of PD mitochondrial cy-
brid cells revealed that they exhibit retention of the
selective complex I defect, increased oxygen radical
production, and increased sensitivity to MPPq-in-
w xduced apoptotic death 32 . In order to determine
whether these SH-SY5Y cybrid cells compensate for
their increased ROS burdens, we assayed cell lines
derived from PD and age-matched control patients
for antioxidant enzyme activities. All activities in PD
cybrids were increased up to three-fold compared to
 .control cybrids Fig. 4 . A 24 h incubation with 50 mM
MPPq increased control cybrids’ protective enzyme
activities significantly to about the same levels as
found in PD cybrids, but did not further significantly
increase PD cybrid scavenging capacities. The one
exception to this observation was the cytoplasmic
CuZn SOD isoform, the activity of which decreased
in both PD and control cells after MPPq exposure.
This may derive from the known inhibition of CuZn
y w xSOD by H O and ONOO 36–38 , although we2 2
Fig. 4. Parkinson’s disease cybrids show increased activities of the major antioxidant enzymes compared to controls, and do not respond
q  .significantly to MPP . Each enzyme is significantly elevated in the PD cybrids relative to controls p-0.05 . Each of the control
q  .cybrids’ enzymes rose significantly after 50 m MPP treatment p-0.05 , while none of the PD cybrids’ rose significantly. The ages of
 .  .  .the PD patients ns6 and control patients ns6 were not significantly different ps0.48, unpaired t-test .
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observed this decrease in activity only in cybrids, not
in native host SH-SY5Y.
4. Discussion
We have shown that following our schedule of
MPTP treatment of black mice, which results in loss
w xof about one-third of nigral dopamine neurons 39 ,
nigrostriatal production of flOH increases with the
greatest relative changes in the ventral midbrain.
Temporally associated with the rise in this potentially
damaging radical species are increases in the nigros-
triatal activities of the major ROS-scavenging en-
zymes, which were also increased in both SY5Y cells
after MPPq exposure and spontaneously in PD cy-
brids. Interestingly, the only predominantly mito-
chondrially-localized antioxidant enzyme, Mn SOD,
exhibited some of the greatest increases relative to
controls in both MPPq-treated SY5Y cells and in PD
 .cybrids greater than 3-fold in both cases .
Although the regulation of the nuclear-encoded
antioxidant enzymes is complex and not well-char-
acterized, they are known to be affected by various
w xoxidative stresses 40–46 . Therefore, it is possible
that their upregulation shown here is due to the
oxidative stress induced by complex I inhibition,
although other factors related to complex I dysfunc-
w xtion such as decreased ATP-production 5,14 , excito-
w x w xtoxicity 14 , or impaired calcium-homeostasis 47
may be involved. That we have observed similar
elevations in antioxidant enzyme activities in both in
vivo and in vitro MPTPrMPPq models of PD and in
PD cybrids relative to controls, argues that despite
the obvious differences between the model systems,
similar stressors might be operating in each case.
Because the only difference between PD and control
cybrids is the source of mitochondria and mtDNA,
PD cybrids appear to be responding to stresses de-
rived from their genetically transmitted complex I
defect.
The elevation of antioxidant enzyme activities in
control cybrids and lack of further significant in-
crease in PD cybrids after MPPq exposure suggests
that the mechanisms for their upregulation are maxi-
mally utilized in the PD cells, at least in the SH-SY5Y
host cells used to make cybrids, and in response to
this regimen of MPPq. Yet, these defenses are inade-
quate, as evidenced by increased baseline ROS in PD
cybrids and enhanced apoptotic cell death after MPPq
w xexposure 32 .
That scavenging capacities for several different
ROS were increased in both experimental MPPq
toxicity and in PD cybrids suggests that in both
situations multiple ROS may be generated, most likely
due to impaired complex I activity. H O , Oy, and2 2 2
flOH have all been detected following complex I
w x w x yinhibition in vitro 7 and in vivo 48 . O can2
combine with NO fl to yield ONOOy, which may
w xdirectly oxidize proteins, lipids, and DNA 9,10 , and
has been found to degrade non-enzymatically to the
fl w x flhighly reactive OH 11,12 . Formation of OH can
also occur via H O degradation catalyzed by Fe2q2 2
 w x.which is abundant in the SN 24 in the Fenton
reaction, providing at least three routes for the gener-
ation of this most destructive of ROS. These toxic
ROS are capable of irreversibly damaging essential
cellular constituents, and most likely contribute to the
w xnigral cell death characteristic of PD 9,10,13,14,20 .
It is interesting to note that the peak in flOH
production in vivo seems to be delayed with respect
to the induction of enzyme activities, compared to the
results in vitro, where ROS levels increased and
peaked 24–36 h before maximal increases in antioxi-
dant enzyme activities. There are several possible
explanations for these observations. First, the time
course of exposure to MPPq is substantially different
in vivo compared to in vitro. With the in vivo MPTP
injections, which occur four times over 48 h, tissue
MPPq levels would be expected to rise rapidly after
each injection, then fall as most MPPq is not re-
tained. MPPq transport into dopamine terminals and
thence into mitochondria in dopamine terminals would
likely occur in a phasic manner following each MPTP
injection. This is in contrast to the in vitro situation
where MPPq is present at a constant low level.
Steady state levels of intracellular and mitochondrial
w qxMPP would be expected to be reached within a
short time.
Because the intracellular stimuli for increased ex-
pression of antioxidant enzymes remain to be fully
determined, it is reasonable to propose a dissociation
between the increases in free radical generation and
increased antioxidant enzyme activities. It is tempting
to assume that oxygen free radical generation is
primarily responsible for stimulating the increase in
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scavenging enzyme activities, but this may not be the
only factor. Our speculation is that the final mito-
w qxchondrial MPP achieved in vivo is higher than that
in vitro, but that the time course of increase in
w qxmitochondrial MPP in vivo is slower than that in
vitro. For this speculation to be tenable and explain
w qxour results, mitochondrial MPP would have to be
related to the level of oxygen free radical production,
and antioxidant enzyme expression would have to be
stimulated either by low levels of oxygen radicals or
 .some other factor s .
Finally, we must consider the differences between
the in vivo and in vitro detection of oxygen species.
The salicylate trapping technique measures only 2,3-
DHB, believed to reflect exclusively the result of
w xhydroxyl radical attack on salicylic acid 25 . In
contrast, the DCF technique used for the in vitro
studies detects multiple reactive oxygen species, in-
cluding hydrogen peroxide, hydroxyl radical, and
w xnitric oxide 30 . These other oxygen species may
have totally different time courses of appearance
during MPPq toxicity compared to hydroxyl radical
alone.
The elevation of Se–GPX activities by Se-supple-
mentation is consistent with reports that standard
tissue culture is Se-deficient with respect to Se–GPX
w xrequirements 35 , and with reports that Se increases
the stability andror translation of GPX mRNA
w xspecies 44,49–51 . The upregulation of GPX protein
levels in response to Se suggests that cells in tradi-
tional tissue culture may be deficient in GPX protein,
and hence subject to excess oxidative stress. The fact
that the addition of MPPq to the Se-treated cells did
not further significantly raise GPX activity suggests
w xthat GPX production was maximal with this Se .
That GRD activities did further increase with com-
bined MPPqrSe suggests that the toxin may have
increased the fraction of GPX protein which was
maximally active, further increasing GSSG produc-
tion, or that MPPq led to oxidation of GSH via
ROS-mediated mechanisms. These results suggest that
w xtreatment of oxidatively-stressed PD tissues 22–24
w xor cybrids 32 with low Se concentrations would
augment their radical-defenses and perhaps impede
cell death. This proposal is consistent with reports of
Se providing protection from the neurotoxic effects
w xof MPTP in rat striatum 52 and the protective role
w xof GPX in the PD brain 53 .
Others have found in postmortem PD brains in-
w x creased SOD 54–56 although it is controversial
.whether only Mn SOD or both isoforms are higher
w x w xand decreased or unchanged CAT 57 and GPX 58
activities, an imbalance which may lead to excess
H O and hence hydroxyl radical production. CuZn2 2
SOD immunoreactivity has also been demonstrated in
w xthe Lewy bodies found in PD brains 59 , suggesting
a correlation between this neuropathological hallmark
w xof PD and free radical scavenging. Damier et al. 53
demonstrated that GPX immunoreactivity is higher in
glial cells surrounding surviving SN dopaminergic
neurons in PD brains, whereas it is lowest in control
brains in the areas most susceptible to PD. This
suggests that surviving neurons elicit an adaptive
response in glial GPX to the processes involved in
PD neurodegeneration. Some reports also have shown
that the activities of GPX and SOD are elevated in
w x w xPD patients’ serum 60 , but not erythrocytes 61 ,
which lack mitochondria, supporting the notion that
the disease is mitochondrial and systemic. Overall,
these studies suggest that antioxidant enzymatic de-
fenses may be crucial for the prevention of cell death
due to ROS-mediated neuronal damage in PD, and
that impairment or limitation of these defenses may
contribute to the pathogenesis of the disease.
If this schema is correct, then further scavenging
of free radicals and inhibition of NOS would provide
relief from the increased ROS burden associated with
PD mitochondria. Involvement of NO fl in experimen-
w xtal MPTP parkinsonism 8–10 suggests an etiologi-
cal role and potential therapeutic target for this
gaseous, diffusible neurotransmitter free radical,
whose normal function in the nervous system is still
w xbeing defined 62,63 . Further upregulation of scav-
enging enzyme capacities may be accomplished with
w xneurotrophins 64,65 , whose expression can be in-
w xduced in vitro by free radicals 66 . This neu-
rotrophin-induced increase in scavenging enzymes
may provide a mechanism for their ability to amelio-
q w xrate MPP neurotoxicity in vitro 67 .
The creation of cybrids with mtDNA from Parkin-
son’s patients offers a novel experimental paradigm
for examining the effects of PD mtDNA on cellular
w xphysiology and pathophysiology 32 . We have shown
that PD cybrids are characterized by a pattern of
oxidative stress and increased antioxidant enzyme
activities remarkably similar to those found in both in
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vitro and in vivo MPPqrMPTP models of PD. These
results are clearly compatible with and strongly sup-
port the hypothesis that mitochondrial dysfunction,
due to mutations in the mitochondrial genes for com-
w xplex I, may underlie sporadic PD 15,32,68 . The
resulting ETC impairments and increased ROS pro-
duction may cause the prominent oxidative stress
characteristic of PD, eventually leading to the death
w xof susceptible neurons 9,13,14,20 . Both deletions
and point mutations have already been found in
w xsporadic PD patients’ mitochondrial DNA 68–70 .
Ultimately, the molecular genetic basis of the com-
plex I defect in PD will be defined following se-
quencing of the mitochondrial genome, as has re-
cently been reported for the selective complex IV
w xdefect in sporadic Alzheimer’s disease 71 .
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